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rachidiennes et pelviennes pouvant expliquer la douleur fessière et/ou la
sciatalgie. Douleurs évaluées par le patient par diminution < ou  50 % de la
douleur préthérapeutique.
Re´sultats.– Seize patients sont revus à quatre mois et 62,5 % de bons résultats
(diminution douleurs  50 %). Deuximème injection de TBA chez 12 patients :
63 % de bons résultats pendant uniquement un mois. Troisième injection chez
trois patients : 100 % de bons résultats un seul mois. Évaluation téléphonique de
14 patients ayant eu de bons résultats initiaux : cinq estiment avoir un bénéfice
partiel persistant à 30 mois en moyenne. Pas de corrélation des résultats avec
l’âge, l’ancienneté du SMP (moyenne 33  44 mois), les lombalgies, la
topographie des douleurs, les modifications électrologiques du réflexe H.
Discussion.– Quatre études publiées objectivent une efficacité statistiquement
significative de la TBA de deux à quatre mois. Dans notre étude ces bons
résultats ne se maintiennent pas non plus au-delà. La répétition des injections de
TBA n’apporte pas d’effet cumulatif et la durée d’efficacité semble même
diminuer. L’intérêt thérapeutique semble donc limité. En revanche, l’efficacité
transitoire à court terme pourrait être utilisée pour confirmer le diagnostic de
SMF puisque cette molécule a essentiellement une action musculaire locale
sans diffusion contrairement aux corticoïdes.
Conclusion.– L’injection de TBA dans le piriforme au cours de formes
chroniques ou rebelles de SMF est devenue pour nous un test diagnostique de
quasi-certitude associé aux données cliniques et paracliniques pour une
meilleure sélection des patients en vue du traitement chirurgical. Néanmoins, le
bien-fondé de cette stratégie reste à confirmer par une étude prospective.
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Therapeutic trials (TT) of botulinum toxin (BT) develop in a wide variety of
diseases of the musculoskeletal system.
Myofascial syndromes have been studied since the physiopathogenic
assumption is an excessive release of acetylcholine causing contractures,
spasms or muscular ‘‘tensions’’ causing referred pain.
TT concern diseases in touch with such muscular tensions: enthesopathy and
tendinopathy (tennis elbow, plantar fasciitis, levator scapulae, rotator cuff,
pubalgia...), some cervicogenic headaches, contractures reaction of complex
regional pain syndrome type I, arthropathies or arthroplasty. Imbalances
agonists/antagonists were also studied (patellofemoral syndrome).
TB is tested in entrapment syndromes by hypertrophy, contracture or abnormal
anatomy of a muscle: piriformis and sciatic nerve, brachial plexus and scalenes,
exertional compartment syndromes, entrapment syndrome of popliteal artery,
supernumerary muscles such as accessory soleus. Unsightly muscular
hypertrophies, mainly the masseter can be reduced as well.
The efficiency of TB on these conditions being analgesic, TB was tested by
intradermal injections for neuropathic pain as well as intra-articular for painful
arthritis in animals and mankind. Fibromyalgia has also led to TT.
These TT have variable methodological levels ranging from randomized
controlled trials to cases reports. Systematic reviews and Cochrane reviews were
published. This treatment appears effective for some diseases, while for others the
results are discordant. All these results must be validated by further studies.
The mode of action of TB by chemodenervation does not explain all observed
effects. The direct action of TB on some neurotransmitters in nociception is
likely. Other mechanisms of direct or indirect action are discussed:
microcirculatory action by changes of muscle contraction, chondroprotective
effect, facilitation of tendon healing...The technical rules of use of TB are identical to those effective in central
neurological diseases but there is no official approval (AMM) for these
locomotor pathologies.
The results are interesting enough even if they require further validation, to
predict a bright future for this new scope of use of TB and to stimulate research
for other effects of TB.
http://dx.doi.org/10.1016/j.rehab.2012.07.125
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Introduction.– Lateral elbow tendinopathy is a common pathology. This
pathology can become very disabling during transition to chronicity. After a
year of evolution, the surgery that is sometimes proposed mainly consists in
detaching the extensor carpi radialis brevis to its proximal insertion. Some
authors have proposed an alternative treatment based on the injection of
botulinum toxin A in the extensor carpi radialis brevis. The benefit of this
therapy remains to be confirmed, especially the long-term effectiveness.Me-
thod.– This is a randomized control trial conducted a prospective, double-blind
placebo. Treatments compared are active treatment (40ui of botulinum toxin A
Dysport diluted in 0.4 ml saline solution injection) with 0,4 ml of a saline
solution injection (placebo). The injection is controlled by an EMG muscle
stimulation in the extensor carpi radialis brevis. The main objective is to assess
the analgesic effect of the injection of botulinum toxin A after 3 months.
Secondary objectives are to examine, in the short term, the duration of pain
relief provided by this therapy and in the medium term, to assess the rate of
recurrence after initial relief. We followed up two groups of 30 patients for one
year.Results.– The two populations are comparable in terms of age, initial pain
VAS and duration of the tendinopathy. We observed a significant decrease
(P = 0.037) of pain in the botulinum toxin group compared to the placebo group
at 3 months (primary endpoint). The pain reduction was also significant between
day 0 (day of injection) and after 3 months. The effectiveness of the treatment
was confirmed after 6 months and 1 year. The recurrence rate at 1 year in the
botulinum toxin group was 4.2%.Discussion.– In agreement with the literature,
our study shows that botulinum toxin is an effective treatment in the lateral
epicondylar tendinopathy muscle resistant to medical treatment well led. This is
a non-invasive treatment, without significant side effects and without recurrence
in the long term. There are very few of recurrence after treatment with
botulinum toxin in this indication in a year follow up.
http://dx.doi.org/10.1016/j.rehab.2012.07.126
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Objectives.– Botulinum toxin injection (BTI) is useful for reducing spasticity,
but we have no information about its effectiveness in post-traumatic
Affection de l’appareil locomoteur (I) / Revue d’E´pide´miologie et de Sante´ Publique 55S (2012) e48–e53e52contractures. Here, we present two case reports suggesting a definite interest in
this domain.
Methods.– We reviewed patients who received BTI (2006–2011) for post-
traumatic contractures of the upper limb. They were assessed for passive and
active range of movement, pain (visual analogic scale) and passive and active
functions.
Case reports.– The first patient suffered from severe and painful post-traumatic
contractures of elbow and wrist flexors, following elbow dislocation, which
severely limited joint extension and use of the hand. Oral treatment and
physiotherapy had a very limited effect. Repeated BTI were performed in
contractured and painful muscles, with limited doses (100U Botox#), each 2–3
months. In the 4–5 days following each injection, contracture and pain were
reduced and this favoured active function of the antagonist muscles. Recovery was
complete after four injection sessions, with fair satisfaction level. The second
patient had been the victim of a traumatic injury of the upper extremity, with
compartment syndrome. She suffered from severe multifocal painful contractures,
impairing daily living, with loss of usage of the limb. Oral treatments and physical
therapy had a modest effect. Iterative BTI were performed every four months
(200U Botox#) for four years, with a partial, recurrent and constant gain on pain,
active motricity, use of the limb, and level of satisfaction
Conclusion.– Following arthroplasty, BTI has yet shown definite effect on
painful contractures of the hip and knee. Here, we present the first reports of
such a symptomatic and functional effect on severe post-traumatic contractures.
Botulinum toxin injections must be considered as a useful treatment for post-
traumatic disabling contractures.
http://dx.doi.org/10.1016/j.rehab.2012.07.127
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Introduction.– Etiologies of exertional leg pain are numerous and may be
associated. This diversity requires a precise diagnostic break-up, and makes its
therapeutic management sometimes complex. How should some abnormalities
(supernumerary muscles, functional popliteal arteries entrapment) be handled
when their imputability in pain is uncertain? Botulinum toxin type A (BTX-A)
has been successfully used for several years in some lesions of the locomotor
apparatus. Our objective is to demonstrate its diagnostic and therapeutic interest
in the chronic compartment syndrome (CCS), functional popliteal artery
entrapment syndrome and the accessory soleus muscle.Observation.– We are
presenting a few studies or case series which are in the process of being analysed
or published. The first open and prospective study demonstrates the diagnostic
and therapeutic interest of BTX-A in 31 patients with antero-external CCS of
the leg of a mean duration of 31 months. Pain disappeared in 97% of cases. A
moderate muscular deficiency is nearly constant and disappears between 1 and 5
months in 94% of cases, preventing only exceptionally an early resumption of
running. Intramuscular pressures, three months after BTX-A, had normalized.
Eight patients presented a recurrence of pain between 6 and 30 months.
In three patients with painful accessory soleus muscle treated by BTX-A
injection within the muscle by stimulodetection, pain had disappeared. Two
patients relapsed at distance.
Five patients presenting with a functional trapped popliteal artery without
anatomical lesion were treated by BTX-A injection. The results are in the
process of analysis. A first patient was able to resume sport, as pain had
disappeared and the echographic dynamic abnormalities had normalized.Dis-
cussion.– The precise use of BTX-A is a useful adjuvant in the diagnostic break-
up of exertional leg pain, in addition to the absolutely essential complementary
tests. It allows precising the imputability of anatomical or functional
abnormalities in the origin of pain. BTX-A has its own therapeutic actionallowing a prolonged amendment of some types of pain. In case of recurrence, it
is an excellent pre-surgical test in non-responding pain with uncertain surgical
results.
http://dx.doi.org/10.1016/j.rehab.2012.07.128
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Introduction.– CRPS remains a phenomenon not clearly understood
physiologically. Three phases follow one another: hot, cold and retractile. A
symptomatic element of dystonia may appear from the cold phase,
characterized by tonic muscle contractions and abnormal postures.
Observation.– A 42 year old woman presents with a epitrochlea fracture of the
left humerus further complicated by ulnar nerve compression which was treated
by arthroscopic surgery. Two years later, with no obvious trigger, the patient
develops pain and swelling of the left arm, and a progressive stiffness of the
hand of attributed to (CRPS). Clinical examination of passive range of motion
revealed the following limitations: shoulder abduction of 308, flexion at 408,
elbow pronation of 608, supination to –458, writs extension of –608, radial
rotation at –208 and pulpo-palmar distance of II to V fingers at 0 mm. The
patient was treated with marcaine for regional local nerve blocks followed by
intensive rehabilitation, without results. Three years later, the patient was
referred to us for further treatment of her dystonia. We used botulinum toxin to
inject the trapezius, teres major, pectoralis major, pronator teres, flexor carpi
radialis, superficial and deep common flexors of the second to fifth fingers. We
used alcohol nerve blocks administered to the palmar muscles, common flexors,
and flexor pollicis longus 15 days later resulting in a clear measurable functional
improvements with shoulder abduction of 808, shoulder flexion of 1508, elbow
pronation 908 and supination to 808, wrist extension at 308, radial rotation of 08,
and the pulpo-palmar distances of 80 mm, 50 mm, 60 mm, 70 mm for second,
third, fourth, and fifth fingers, respectively.
Discussion.– The literature on CRPS dystonia is very scarce, the use of
botulinum toxin as well as intensive active and passive rehabilitation in
conjunction with psychotherapy can be an effective therapeutic combination.
Further reading
M Revel, S Aloui, S Poiraudeau, MA mayoux-benhamou, B Armor, Forme
froide d’emblée d’algodystrophie du pied ou algodystonie? Ann Réadaptation
Méd Phys 1998; 41:485–90
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Introduction.– Botulinum toxin (BT) can be used in the treatment of neck and
upper limb pain and in the management of low back pain with or without
sciatica. Its use and justification in these indications are based on the myofascial
pain concept according to Travell, which would be a malfunction of the motor
endplate with excessive release of acetylcholine.
